Kenya - English - Pharmacy and Poisons Board

metrovet(k)ltd po box 1601-00100 nairobi - albendazole 2500mg - tablet - albendazole 2500mg - antibacterials for systemic use: tetracyclines

Kenya - English - Pharmacy and Poisons Board

metrovet(k)ltd po box 1601-00100 nairobi - albendazole 300mg - tablet - albendazole 300mg - antibacterials for systemic use: tetracyclines

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

arpimed llc - albendazole - tablets chewable - 400mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

arpimed llc - albendazole - tablets chewable - 400mg

United States - English - NLM (National Library of Medicine)

dr.reddys laboratories inc - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets. risk summary based on findings from animal reproduction studies, albendazole may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st  trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. i

United States - English - NLM (National Library of Medicine)

central texas community health centers - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 200 mg - albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albenza is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albenza is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albenza. pregnancy category c. there are no adequate and well-controlled studies of albenza administration in pregnant women. albenza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. albenza should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. obtain pregnancy test prior to prescribing albenza to women of reproductive potential. advise women of reproductive potential to use effective birth control for the duration of albenza therapy and for

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 200 mg - albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albenza is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albenza is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albenza. pregnancy category c. there are no adequate and well-controlled studies of albenza administration in pregnant women. albenza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. albenza should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. obtain pregnancy test prior to prescribing albenza to women of reproductive potential. advise women of reproductive potential to use effective birth control for the duration of albenza therapy and for

United States - English - NLM (National Library of Medicine)

amedra pharmaceuticals llc - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 200 mg - albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albenza is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albenza is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albenza. pregnancy category c. there are no adequate and well-controlled studies of albenza administration in pregnant women. albenza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. albenza should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. obtain pregnancy test prior to prescribing albenza to women of reproductive potential. advise women of reproductive potential to use effective birth control for the duration of albenza therapy and for

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 247.5 g in 250 g

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - albendazole - unknown - albendazole carbamate-benzimidazole active 0.0 - active constituent